Evidence map›Paper›PMID 41035003›Full record

ArticleStem cell research & therapy2025

Magnetic engineered bone mesenchymal stem cells-derived exosomes for targeted acute lung injury therapy.

Yunjuan Wang, Jiayan Huang, Yanli An, Yaqi Li, Shuanglong Chen, Yuting Mei, Dongfang Liu, Qiusha Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Extracellular vesicle-mediated mechanisms and therapeutic potential in acute lung injury.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Review
  3. Trained immunity in respiratory diseases: Mechanisms of action and intervention strategies.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yunjuan Wang *Medical School, Southeast University, No. 87, Dingjiaqiao, Nanjing, 210003, Jiangsu, China.
Jiayan Huang *Institute of Biomedical Innovation, Nanchang University, Nanchang, 330031, Jiangxi, China.
Yanli AnNurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Center of Interventinal Radiology &Vascular Surgery, Department of Radiology, Medical School, Zhong da Hospital, Southeast University, No. 87, Dingjiaqiao, Nanjing, 210003, Jiangsu, China.
Yaqi LiWuxi School of Medicine, Jiangnan University, Jiangsu, 214122, Wuxi, China.
Shuanglong ChenMedical School, Southeast University, No. 87, Dingjiaqiao, Nanjing, 210003, Jiangsu, China.
Yuting MeiDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210015, China.
Dongfang LiuMedical School, Southeast University, No. 87, Dingjiaqiao, Nanjing, 210003, Jiangsu, China. liudf@seu.edu.cn.
Qiusha TangMedical School, Southeast University, No. 87, Dingjiaqiao, Nanjing, 210003, Jiangsu, China. panyixi-tqs@163.com.

Funding

China Postdoctoral Science Foundation 2023M743559Jiangsu Provincial Key Laboratory of Critical Care Medicine JSKLCCM-2022-02-016Jiangxi Provincial Key Laboratory of Child Development 2024SSY06191Social Development Project of the Key Research and Development Plan of Jiangsu Province BE2023660The National Natural Science Foundation of China 82473350
6 · The paper itself

Abstract

backgroundAcute lung injury (ALI) is a critical pulmonary condition characterized by high morbidity and mortality rates. Recent studies have highlighted the therapeutic potential of engineered exosomes derived from mesenchymal stem cell (MSC) in modulating the inflammatory response in ALI. Here, a novel approach was developed to fabricate engineered bone mesenchymal stem cells (BMSCs) derived exosomes by utilizing superparamagnetic iron oxide nanoparticles (SPIONs) and an alternating magnetic field (AMF) to precondition BMSCs. This study evaluated and compared the therapeutic potential of different groups of engineered exosomes in ALI mice model and analyzed their underlying mechanisms using high-throughput sequencing.

methodsBMSCs were isolated from SD rats and subjected to treatment with SPIONs and/or an AMF. Following this, we established a lipopolysaccharide (LPS)-induced ALI mice model and evaluated the therapeutic efficacy of exosomes from different groups by administering them via tail vein injection. The expression profiles of microRNAs (miRNAs) in exosomes were compared to explore the mechanism of regulating inflammatory response and ameliorating lung injury.

results25 µg/mL SPIONs and 3mT AMF were the best conditions for preparing engineered exosomes, which reduced the level of pro-inflammatory factors and had the most significant effect in repaired lung damage in vivo. The transfection of miR-145-5p mimics enhanced Bronchial Epithelium transformed with Ad12-SV40 2B (BEAS-2B) cells viability and reduced relevant inflammation expression in vitro experiments.

conclusionThe engineered exosomes obtained by low dose SPIONs combined with AMF can help regulate the level of inflammatory factors and improve lung injury. Targeted regulation of kruppel-like factor 5 (KLF5) by exosomal miR-145-5p and inhibition of the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway play a key role in this vitro process.

Indexed as

Acute Lung InjuryExosomesMesenchymal Stem CellsAnimalsDisease Models, AnimalLipopolysaccharidesMagnetic Iron Oxide NanoparticlesMaleMiceMicroRNAsRatsRats, Sprague-DawleyLipopolysaccharidesMicroRNAsAcute lung injuryAlternating magnetic fieldEngineered exosomesInflammationSuperparamagnetic iron oxide nanoparticles

Identifiers

PMID41035003
PMCPMC12487277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.